A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest that high DSG2 expression is…
Myeloma
A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people…
Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death, a new study shows. “For…
On some afternoons, while my mum and I are at the hospital, I notice how long it takes just to wait for our turn. Whether…
It’s the most wonderful time of the year! Some people have Christmas in July. Or the Fourth of July. I have nine days of fandom…
Dosing has begun in a Phase 3 clinical trial testing whether the antibody therapy Gamunex-C (immune globulin injection [human], 10% caprylate/chromatography purified) can help prevent…
The U.S. Food and Drug Administration (FDA) has set a date for next year by which it will decide whether or not to approve a…
Some days, I watch my mother try to stand, and my breath catches. The doctors have warned us about bone weakness — how…
For seven years, I have kept up on developments in multiple myeloma research. I follow the latest treatments, the newest studies, and…
The U.S. Food and Drug Administration (FDA) has approved a new version of Sarclisa (isatuximab), an approved treatment for multiple myeloma sold by…
